Heparin sodium
Calciparine, Embolex, Lipo-hepin, Liquaemin, Panheprin (heparin sodium) is an oligosaccharide pharmaceutical. Heparin sodium was first approved as Calciparine on 1982-01-01. It is used to treat cerebral infarction, coronary thrombosis, myocardial infarction, postoperative complications, and pulmonary embolism amongst others in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dihydroergotamine mesylate
+
Heparin sodium
+
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMBOLEX | Novartis | N-018885 DISCN | 1984-11-30 | 2 products |
Hide discontinued
Heparin calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CALCIPARINE | Sanofi | N-018237 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Heparin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019952 RX | 1992-07-20 | 1 products, RLD, RS |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019952 RX | 1992-07-20 | 2 products, RLD, RS |
| HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | B. Braun Medical | N-019953 RX | 1992-07-20 | 1 products, RLD, RS |
| HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Baxter | N-018609 RX | 2020-04-23 | 1 products |
| HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Baxter | N-018609 RX | 1982-04-28 | 1 products |
| HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Baxter | N-018609 RX | 1982-04-28 | 1 products |
| HEPARIN SODIUM | Fresenius Kabi | N-017029 RX | 2011-03-31 | 1 products, RLD, RS |
| HEPARIN SODIUM PRESERVATIVE FREE | Fresenius Kabi | N-017029 RX | 1986-04-28 | 2 products, RLD, RS |
| HEPARIN SODIUM IN PLASTIC CONTAINER | Fresenius Kabi | N-017029 RX | 1985-12-05 | 4 products, RLD, RS |
| HEPARIN SODIUM | Fresenius Kabi | N-017029 RX | 1982-01-01 | 3 products, RLD, RS |
Show 12 marketed
Show 59 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| heparin sodium | ANDA | 2023-04-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cerebral infarction | — | D002544 | I63 |
| coronary thrombosis | EFO_1000883 | D003328 | I21 |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| postoperative complications | — | D011183 | — |
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
| thromboembolism | HP_0001907 | D013923 | — |
| thrombophlebitis | HP_0004418 | D013924 | — |
| unstable angina | EFO_1000985 | D000789 | I20.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AB: Heparin group antithrombotic drugs
— B01AB01: Heparin
— B01AB51: Heparin, combinations
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC30: Platelet aggregation inhibitor combinations excl. heparin
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05B: Antivaricose therapy drugs
— C05BA: Heparins or heparinoids for topical use
— C05BA03: Heparin
— C05BA53: Heparin, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA14: Heparin
Clinical
Clinical Trials
497 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 2 | 3 | 10 | 10 | 13 | 37 |
| Covid-19 | D000086382 | U07.1 | 4 | 12 | 11 | 8 | 6 | 32 | |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 2 | 4 | 11 | 5 | 9 | 30 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 2 | 2 | 6 | 10 | 2 | 22 |
| Thrombosis | D013927 | 1 | 3 | 4 | 2 | 11 | 20 | ||
| Coronary artery disease | D003324 | I25.1 | — | 5 | 1 | 8 | 4 | 18 | |
| Neoplasms | D009369 | C80 | 2 | 2 | 6 | 1 | 6 | 16 | |
| Catheter-related infections | D055499 | 1 | — | 2 | 3 | 6 | 12 | ||
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | 2 | 2 | 3 | 6 | 12 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 2 | 3 | 6 | 2 | 1 | 11 |
Show 66 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | 1 | 1 | — | — | 10 | ||
| Septic shock | D012772 | A48.3 | — | 3 | 1 | — | 2 | 6 | |
| Critical illness | D016638 | — | 2 | 2 | — | 1 | 5 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | 3 | 5 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 2 | — | 2 | 4 | |
| Colorectal neoplasms | D015179 | — | 1 | 3 | — | — | 3 | ||
| Proliferative vitreoretinopathy | D018630 | EFO_1001129 | — | — | 3 | — | — | 3 | |
| Upper extremity deep vein thrombosis | D056824 | — | 2 | 1 | — | 1 | 3 | ||
| Burns | D002056 | T30.0 | — | 1 | 1 | — | 2 | 3 | |
| Balloon angioplasty coronary | D015906 | EFO_0003951 | — | 1 | 2 | — | — | 3 |
Show 30 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 3 | — | — | 2 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 6 | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 2 | — | — | — | 2 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | 1 | — | — | 1 | 2 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | 2 | — | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | 1 | |
| Embolic stroke | D000083262 | — | 1 | — | — | — | 1 | ||
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | — | — | — | 1 | |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | 1 | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | 1 | — | — | — | 2 | 3 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | — | 1 |
| Thrombophlebitis | D013924 | HP_0004418 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 3 | 3 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | 2 | 2 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Hyperlipoproteinemia type i | D008072 | Orphanet_411 | E78.3 | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 2 | 2 | |
| Optical coherence tomography | D041623 | — | — | — | — | 1 | 1 | ||
| Cytokine release syndrome | D000080424 | D89.83 | — | — | — | — | 1 | 1 | |
| Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | 1 | 1 | ||
| Urolithiasis | D052878 | N20-N23 | — | — | — | — | 1 | 1 | |
| Carotid artery injuries | D020212 | S15.0 | — | — | — | — | 1 | 1 |
Show 44 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HEPARIN SODIUM |
| INN | heparin sodium |
| Description | Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Since heparins depend on the activity of antithrombin, they are considered anticoagulants. Specifically it is also used in the treatment of heart attacks and unstable angina. It is given intravenously or by injection under the skin. Other uses for its anticoagulant properties include inside blood specimen test tubes and kidney dialysis machines.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9005-49-6 |
| RxCUI | 5224 |
| ChEMBL ID | CHEMBL1201657 |
| ChEBI ID | — |
| PubChem CID | 22833565 |
| DrugBank | DB01109 |
| UNII ID | ZZ45AB24CA (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 257,051 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,049 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more